An improved method of delivering a sclerosing agent for the treatment of a malignant pleural effusion
Ended Project Grant Awarded Last action
- Award ID
- SB1CA210696
- Recipient
-
TDL Innovations LLC UEI MU8UKBNPF3J5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,177,401
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Funding
-
- $778,707.09 Federal
- $398,694.00 Non-federal
- Place of performance
- New Jersey, USA
Award details come from USAspending.gov.
Description
- Abstract
- We are developing an improved method to treat patients with malignant pleural effusions (MPE), a serious condition that occurs in 175,000 patients in the US each year, affecting between 7 to 15% of all cancer patients. MPE results in an excessive accumulation of fluid in the pleural cavity, frequently leaving the patient to suffer from shortness of breath and overall poor quality of life. Management of MPE is palliative and the main problem with the current techniques such as pleurodesis is its clinical failure rate due to the inefficient and non-uniform distribution of the sclerosing agent. Currently, there is no standardization or consensus within the medical community on the optimal delivery technique for a sclerosing agent because of the tradeoffs and variability in patient satisfaction, efficacy, costs, and complexities. Our focus is on the development of an improved clinical approach to administering a sclerosing agent, which will overcome the problems with standard of care. In phase i feasibility studies, we developed and evaluated several foam formulations and have selected a lead candidate. We fully characterized the lead, demonstrating its desired adhesiveness, gelation and reverse thermo-sensitive properties as well as its efficacy in an animal model. These results enabled US to optimize the lead formulation and in parallel select the final design of our proprietary delivery system with important end user input during our active phase II project. The fully functional prototype will be evaluated for safety and efficacy during biocompatibility studies conducted under GLP conditions, in order to prepare a data package for an IND application to the food and drug administration. Once successfully completed, these phase II results will prepare US to initiate clinical trials where we will test the combination product in collaboration with several prestigious clinical partners who are an important part of our team. The proposed CRP aligns with the corporate strategy and timeline and would enable US to develop a clear regulatory path and help US accelerate the process of obtaining IND approval. Our multidisciplinary team lead by an experienced cardiothoracic surgeon and medical product developer, has the demonstrated requisite expertise ranging from innovating in chemical and mechanical engineering, navigating the FDA regulatory pathway, successfully commercializing pharmaceutical and medical device products, to successfully exiting companies. Working together with these experts and an experienced regulatory firm, we intend to accomplish an important milestone toward commercialization. The funding sought through the sbir CRP program will further enable US to leverage our network for securing third party investors, many whom are already expressing interest. Our novel approach is expected to significantly impact the current clinical standard of care and result in markedly improved clinical patient outcomes with a simple, minimally invasive procedure.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | -$18,681 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $398,694 | $0 | |
| Original award | $398,694 | $398,694 |
Quick answers
Who received award SB1CA210696?
SB1CA210696 was awarded to TDL Innovations LLC by National Cancer Institute (National Institutes of Health) on June 1, 2021.
How much is award SB1CA210696 worth?
$1,177,401 has been obligated on SB1CA210696: $778,707 in federal funding and $398,694 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award